NovaBridge Biosciences Shares Climb on >10-Letter Gains in VIS-101 Trial
NovaBridge Biosciences’ Phase 2a VIS-101 study showed >10 ETDRS letter gains and 100–150 µm subfield reductions in 3 mg and 6 mg AMD cohorts of 38 patients, with no dose-limiting toxicities. The company plans a Phase 2b dose-finding study in H2 2026 and a global Phase 3 program in 2027.
1. Phase 2a VIS-101 Topline Results
VIS-101, a treatment for wet AMD, demonstrated mean Best Corrected Visual Acuity improvements exceeding 10 ETDRS letters and median subfield thickness reductions of 100–150 µm in both 3 mg and 6 mg cohorts, signaling rapid and durable efficacy in the 38-patient trial.
2. Safety and Patient Cohort
The study enrolled 38 wet AMD patients in China and reported a favorable safety profile with no dose-limiting toxicities across both dose levels, positioning VIS-101 as a potential best-in-class therapy for retinal vascular diseases.
3. Future Clinical Plans
Building on these results, NovaBridge Biosciences intends to initiate a dose-determining Phase 2b study in the second half of 2026, followed by a global Phase 3 program in 2027 to support potential regulatory filings.
4. Stock Performance and Technical Indicators
Shares jumped 8.86% in early trading, reversing a 23.08% decline over the past 12 months. The stock trades above its 20-day and 50-day SMAs with a neutral RSI around 52 and a bullish MACD crossover, facing resistance at $4.50 and support near $3.50.